Roche Holding AG (RO.EB) said Tuesday that new data from two ongoing phase-III trials evaluating etrolizumab in patients with inflammatory bowel disease, or IBD, indicated that patients showed an improvement.
The trials are part of a global phase-III program for etrolizumab in patients with ulcerative colitis and Crohn's disease, two types of IBD.
Continue Reading Below
Both studies found that etrolizumab was well tolerated, with a frequency of adverse events comparable with a placebo, Roche said.
The Centers for Disease Control and Prevention estimates that 3 million adults in the U.S. have been diagnosed with IBD.
Write to Alberto Delclaux at firstname.lastname@example.org
(END) Dow Jones Newswires
October 31, 2017 03:00 ET (07:00 GMT)